Lumida
/ANIP
⌘K
ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

ANIP
$72.83USD-0.93%-0.68 today

MARKET CAP

1.7B

P/E (TTM)

18.5x

FWD P/E

DAY RANGE

$73 – $74

52W RANGE

$70
$100

AI Summary

Stalk
Sell NowMedium

ANIP is in a Stage 4 decline with a dominant downtrend, trading below all key EMAs and the 50-day SMA. Short-term momentum remains negative without evidence of exhaustion, while volume spikes on down days signal distribution. Medium-term bias is firmly bearish following failed support tests and moving-average resistance. Selling into the 9/20-day EMA confluence is advised immediately.

  • Q2 net revenue $266M (+25.9% YoY) led by Cortrophin Gel
  • Rare disease sales rose 30.7% to $135.8M
  • Mgmt cut full-year Cortrophin Gel revenue guidance to $520–540M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$216.1M$316.4M$486.8M$614.4M$883.4M
YoY %+3.7%+46.4%+53.9%+26.2%+43.8%
P / Sales2.7x2.1x2.1x1.7x1.9x
EV / Sales4.1x3.2x2.6x2.9x2.6x
Gross Profit, Adj.$115.5M$177.6M$305.3M$364.2M$542.1M
YoY %-4.8%+53.7%+71.9%+19.3%+48.8%
Margin %53.5%56.1%62.7%59.3%61.4%
EV / Gross Profit7.7x5.8x4.1x4.9x4.2x
EBITDA, Adj.$19.1M$33.9M$107.9M$70.6M$203.7M
YoY %-34.4%+77.7%+218.1%-34.6%+188.6%
Margin %8.8%10.7%22.2%11.5%23.1%
EV / EBITDA46.8x30.2x11.7x25.2x11.2x
EBIT$-39.8M$-29.6M$48.1M$-4.8M$111.5M
YoY %-148.5%+25.6%+262.5%-109.9%+2440.4%
Margin %-18.4%-9.4%9.9%-0.8%12.6%
EV / EBIT-22.4x-34.6x26.3x-373.5x20.5x
Net Income$-42.8M$-49.5M$15.5M$-20.1M$70.2M
YoY %-89.8%-15.7%+131.2%-230.2%+448.5%
Net Margin-19.8%-15.7%3.2%-3.3%7.9%
EPS (GAAP)-$3.40-$3.05$0.85-$1.04$3.32
YoY %-80.9%+10.3%+127.9%-222.4%+419.2%